Conference Insider
In one survey of payers, 47.6% reported having pathways for multiple myeloma, with another 19.1% citing the cancer type as a high priority for pathway development, Edmund Pezalla, MD, MPH, chief executive officer of Enlightenment BioConsult, explained at the AMCP Annual Meeting 2017.
Oncology…